Polycyclo Ring System Patents (Class 514/569)
-
Publication number: 20150031767Abstract: Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum lactamase (ESBL) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli. The fulvic acid can be provided in combination with one or more antibiotics from the class of carbapenems or polymyxin antibiotics.Type: ApplicationFiled: March 6, 2013Publication date: January 29, 2015Applicant: NATRACINE UK LIMITEDInventors: Stephen William Leivers, Peter Warn
-
Patent number: 8932625Abstract: An adhesive patch comprising a substrate and a pressure-sensitive adhesive base, wherein the pressure-sensitive adhesive base comprises a rubbery polymer having double bonds in the main chain and a nonsteroidal anti-inflammatory analgesic and contains a UVA screening agent and/or UVB screening agent as a stabilizer for the rubbery polymer. The adhesive patch is excellent in the stability of the pressure-sensitive adhesive base and in drug infiltration into the skin.Type: GrantFiled: December 24, 2004Date of Patent: January 13, 2015Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yoshiaki Hashimoto, Yasunori Takada, Miyuki Shinmura, Shigeo Suzuki, Kiyomi Tsuruda, Koichi Ikesue
-
Publication number: 20150011636Abstract: Compounds that may have anti-inflammatory activity have the general formula (I): Wherein R1, R2, R3 are each independently H or a C1-4 alkyl group or a C2-4 acyl group; R4 and R5 are each independently H or a group of formula —SO3R6, wherein R6 is H or a C1-4 alkyl group or a C2-4 acyl group; with the proviso that at least one of R4 and R5 is a group of formula —SO3R6, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 2, 2014Publication date: January 8, 2015Applicant: LABORATOIRE MEDIDOM SAInventors: Stefano CARLINO, Alessandro DI NAPOLI
-
Publication number: 20150011637Abstract: Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the following diffraction angles: 2.9±0.2°, 6.5±0.2°, 12.6±0.2°, 13.1±0.2° and 20.6±0.2°.Type: ApplicationFiled: January 10, 2013Publication date: January 8, 2015Inventors: Zhijun Tang, Yubin Liu, Bingming He, Jun Yang, Xiaoming Ji
-
Publication number: 20150010599Abstract: Methods and compositions for reducing bladder spasms are disclosed. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory agent (NSAID). In another embodiment, a method for reducing bladder spasms comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of at least one prostaglandin (PG) pathway inhibitor, wherein the at least one PG pathway inhibitor is not acetaminophen or an NSAID.Type: ApplicationFiled: September 24, 2014Publication date: January 8, 2015Inventor: David A. DILL
-
Publication number: 20150005384Abstract: Provided are a crystal form A of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form A has characteristic peaks at the following diffraction angles: 2.9±0.2°, 13.6±0.2°, 17.3±0.2° and 18.6±0.2°.Type: ApplicationFiled: January 10, 2013Publication date: January 1, 2015Inventors: Zhijun Tang, Yubin Liu, Bingming He, Jun Yang, Xiaoming Ji
-
Patent number: 8921423Abstract: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.Type: GrantFiled: December 1, 2010Date of Patent: December 30, 2014Assignee: Galderma Research & DevelopmentInventors: Michael Graeber, Janusz Czernielewski
-
Publication number: 20140377343Abstract: The present invention relates to a pharmaceutical formulation, characterized by comprising flurbiprofen or a pharmaceutically acceptable salt of flurbiprofen, diacerein or a pharmaceutically acceptable salt of diacerein, as well as at least one or a properly-proportioned mixture of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or polyvinyl alcohol-polyethylene glycol copolymer.Type: ApplicationFiled: December 20, 2012Publication date: December 25, 2014Inventors: Umit Cifter, Ali Turkyilmaz, Nur Pahlivan Akalin, Sibel Zenginer
-
Publication number: 20140363402Abstract: The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RAR? agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.Type: ApplicationFiled: August 31, 2011Publication date: December 11, 2014Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Masahiro Iwamoto, Maurizio Pacifici
-
Publication number: 20140350110Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.Type: ApplicationFiled: July 7, 2014Publication date: November 27, 2014Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Helmut Heinrich BUSCHMANN, Lluis SOLA CARANDELL, Jordi BENET BUCHHOLZ, Jordi Carles CERON BERTRAN, Carlos Ramon PLATA SALAMAN, Nicolas TESSON
-
Publication number: 20140350111Abstract: Methods for treatment of and prophylaxis against hemorrhoids are disclosed, including methods of treatment of and prophylaxis against hemorrhoids comprising administering naproxen to an individual.Type: ApplicationFiled: September 7, 2012Publication date: November 27, 2014Inventor: Guy Alan Hale
-
Publication number: 20140343079Abstract: The invention provides compounds of formulae (I), (II), (III), and (IV): and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease.Type: ApplicationFiled: September 13, 2012Publication date: November 20, 2014Applicants: Behalf of Arizona State UniversityInventors: Carl E. Wagner, Peter W. Jurutka, Pamela A. Marshall
-
Patent number: 8883233Abstract: Disclosed is an animal feed composition that comprises free indole acetic acid (free IAA) or a derivative thereof. Also disclosed is a method for enhancing animal growth by feeding the animal with a composition according to the invention. Further disclosed is the use of free IAA or a derivative thereof in a method of therapy of animals in need of a growth-promoting treatment, such as immunocompromised animals, animals with a growth deficit or slow-growing animals. Disclosed is the use of free IAA or a derivative thereof for the preparation of a therapeutical composition for increasing the growth rate and/or the feed conversion rate and/or the immunity of animals in need of such a treatment, in particular, immunocompromised or slow-growing animals. A composition may be in the form of a food or feed supplement.Type: GrantFiled: July 13, 2012Date of Patent: November 11, 2014Assignee: Veijlen N.V.Inventors: Hurbert Jean Marie Francois Gillessen, Christian Rebiere
-
Patent number: 8883850Abstract: The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.Type: GrantFiled: May 23, 2011Date of Patent: November 11, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Douglas C. Beshore, Christina Ng DiMarco, Scott D. Kukuk
-
Patent number: 8883148Abstract: A method for treating, preventing or reducing the risk of joint destruction in a subject who suffers from a joint or musculoskeletal disease. The method comprises administering a histone deacetylase (HDAC) inhibitor or in conjunction with other agents to inhibit degradation and resorption of cartilage and bone in the joint.Type: GrantFiled: March 14, 2005Date of Patent: November 11, 2014Assignee: ASAN Laboratories Company (Cayman), LimitedInventor: Yih-Lin Chung
-
Publication number: 20140329903Abstract: The present disclosure relates to compounds to be used in a low dose in treatment of neurodegenerative diseases or disorders. It also relates to methods for treatment of a neurodegenerative diseases or disorders.Type: ApplicationFiled: August 7, 2012Publication date: November 6, 2014Applicant: ACADIA PHARMACEUTICALS INC.Inventors: Ethan S. Burstein, Roger Olsson, Krista M. McFarland
-
Publication number: 20140322148Abstract: Described herein are topical oil-based formulations that find use in the treatment of alopecia, i.e., hair loss, and in the promotion of hair growth.Type: ApplicationFiled: November 20, 2012Publication date: October 30, 2014Inventor: Adrianna Janell JACKSON
-
Publication number: 20140323558Abstract: The invention provides well-defined compounds that are either EP2 agonists, EP4 agonists, or mixed EP2/EP4 agonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the EP2 and/or EP4 receptors.Type: ApplicationFiled: April 29, 2014Publication date: October 30, 2014Applicant: Allergan, Inc.Inventor: David W. Old
-
Patent number: 8865689Abstract: Methods and compositions for treating and/or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.Type: GrantFiled: March 7, 2012Date of Patent: October 21, 2014Assignee: TWi Biotechnology, Inc.Inventors: Mannching Sherry Ku, Chih-Kuang Chen, Wei-Shu Lu, I-Yin Lin
-
Publication number: 20140309195Abstract: Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration. Also provided herein are methods for promoting skin regeneration and wound healing.Type: ApplicationFiled: January 8, 2014Publication date: October 16, 2014Applicant: INTERNATIONAL STEM CELL CORPORATIONInventors: Rodolfo Gonzalez, Maxim Poustovoitov, Ruslan Semechkin
-
Publication number: 20140308265Abstract: The claimed invention is directed to compositions and methods effective in preventing microbial contamination or reducing microbial count associated with a contaminated surface, comprising a biocidal system comprised of a primary biocide, a pH buffer agent, a surfactant, all in an aqueous based carrier, wherein the compositions may be considered environmentally friendly.Type: ApplicationFiled: November 6, 2012Publication date: October 16, 2014Inventors: Burt R. Sookram, John W. Veenstra
-
Publication number: 20140308241Abstract: Described are biomarkers including TOX useful for the diagnosis or prognosis of T cell malignancy. A level of a biomarker is determined in a sample from a subject and compared to a control level, wherein an increased level of the biomarker in the sample relative to the control level indicates that the subject has T cell malignancy. The T cell malignancy may be a cutaneous T cell lymphoma (CTCL) such as mycosis fungoides or Sezary syndrome.Type: ApplicationFiled: November 16, 2012Publication date: October 16, 2014Inventors: Youwen Zhou, Yuanshen Huang, Yang Wang, Ming-wan Su
-
Publication number: 20140308223Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.Type: ApplicationFiled: March 21, 2014Publication date: October 16, 2014Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Michael GRAEBER, Janusz CZERNIELEWSKI
-
Publication number: 20140303223Abstract: The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RAR? agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.Type: ApplicationFiled: June 18, 2014Publication date: October 9, 2014Inventors: Masahiro IWAMOTO, Maurizio PACIFICI
-
Publication number: 20140302163Abstract: A process for preparing conventional water sources for providing “ideal state” cellular wellness benefits via topical hydration and natural transdermal, epithelial or epicellular absorption. The invention's process considers preconditioned water sources that have removed solids, dissolved solids, contaminants—both organic and inorganic and subsequently the method purifies the water respective of removing pathogens, and structures the water for cellular uptake in the form of vicinal grade water, with improved characteristics of ideal frequency, cluster size, pH, before safely introducing negative ORP (highly ionized state) to the water structure and organic nutrients or other supplemental pharmaceutical grade organic materials onto the skin or epithelial/epicellular environments surrounding tissue and cells.Type: ApplicationFiled: March 16, 2014Publication date: October 9, 2014Applicant: Subtech Industries, LLCInventors: David Sanchez, Len Deweerdt
-
Publication number: 20140303252Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent.Type: ApplicationFiled: April 30, 2014Publication date: October 9, 2014Applicant: Supernus Pharmaceuticals, Inc.Inventors: Argaw Kidane, Padmanabh P. Bhatt
-
Patent number: 8853275Abstract: A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy.Type: GrantFiled: May 18, 2009Date of Patent: October 7, 2014Assignee: Galderma Research & DevelopmentInventors: Jean-Charles Dhuin, Nabil Kerrouche, Stéphanie Arsonnaud, Pascale Soto
-
Publication number: 20140296340Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).Type: ApplicationFiled: June 11, 2014Publication date: October 2, 2014Inventors: Marie-Line Abou Chacra VERNET, Denis GROSS, Christian LOESCHE, Michel PONCET
-
Publication number: 20140296270Abstract: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.Type: ApplicationFiled: April 15, 2014Publication date: October 2, 2014Applicant: Baylor College of MedicineInventors: David J. Tweardy, Xuejun Xu, Moses M. Kasembeli
-
Publication number: 20140296341Abstract: The present invention relates to formulations comprising a solid dispersion product of an active agent having at least one of a hydrogen bond donor moiety (e.g. ibuprofen, fenofibric acid or naproxen) and a proton donor moiety and a pharmaceutically acceptable polyvinyllactam polyvinylacetate poly(alkylene glycol) graft copolymer, and to methods for preparing such formulations.Type: ApplicationFiled: September 21, 2012Publication date: October 2, 2014Inventors: Samuel Kyeremateng, Gerd Woehrle, Svenja Warnecke, Simon Kullmann, Ullrich Westedt, Jürgen Weis
-
Patent number: 8846758Abstract: Methods for treating abnormal glycosylated hemoglobin (HbA1c) levels in a patient in need thereof, wherein the provided methods comprise administering to a patient in need a therapeutically effective amount of an Interleukin-1? modulator. Also, the invention provides compositions comprising at least one lipid modifying agent and an IL-1? modulator.Type: GrantFiled: July 19, 2012Date of Patent: September 30, 2014Assignee: TWi Biotechnology, Inc.Inventors: Mannching Sherry Ku, Chih-Kuang Chen, Wei-Shu Lu, Chih-Ming Chen, I-Yin Lin
-
Patent number: 8846083Abstract: A process for local permucosal diffusion of amino acid salts of low dosage lipophlic non-steroidal anti-inflammatory or anti-mycotic molecules for an aqueous medicine for the treatment of bucco-pharyngeal ailments is disclosed. Compositions and tablets implementing this diffusion process are also disclosed.Type: GrantFiled: February 1, 2005Date of Patent: September 30, 2014Inventors: Philippe Perovitch, Marc Maury
-
Patent number: 8846039Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.Type: GrantFiled: August 31, 2007Date of Patent: September 30, 2014Assignee: Asan Laboratories Company (Cayman), LimitedInventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
-
Publication number: 20140288179Abstract: An improved method for administering treprostinil or a salt is described that allows for use of the diluted solution prior to administration for a longer period of time to avoid wasted medication.Type: ApplicationFiled: June 12, 2014Publication date: September 25, 2014Inventors: David Zaccardelli, Roger Andrew Jeffs
-
Publication number: 20140275262Abstract: There is provided individual polymorphic forms of treprostinil and pharmaceutical formulations comprising the same, methods of making and using the sameType: ApplicationFiled: March 7, 2014Publication date: September 18, 2014Applicant: United Therapeutics CorporationInventors: Ken Phares, Michael Scannell
-
Publication number: 20140275263Abstract: Provided are pharmaceutical carriers suitable based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by formulated for topical administration to the eye.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: EyeCRO, LLCInventors: Ronald A. Wassel, Fadee G. Mondalek, Rafal A. Farjo, Alexander B. Quiambao, Didier J. Nuño
-
Publication number: 20140256730Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.Type: ApplicationFiled: January 13, 2014Publication date: September 11, 2014Applicant: Corsair Pharma, Inc.Inventors: Cyrus K. BECKER, Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
-
Publication number: 20140256818Abstract: Described herein is a process for preparing nano-suspensions, wherein the process comprises: providing an admixture of at least one active pharmaceutical compound, an aqueous dispersion medium, and milling media and applying thereto acoustic energy having a frequency of from about 10 hertz to 1000 hertz and which supplies a linear acceleration of from about 10 G?s to about 100 G?s (where “G” is the force of gravity) for a period sufficient to supply a nano-suspension having a D50 of less than about 1 micron, preferably less than about 500 nm. Described also are nano-suspensions having novel properties prepared via the inventive process.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Dennis Leung, Todd D. Nelson, Timothy A. Rhodes, Elizabeth Kwong
-
Publication number: 20140249232Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.Type: ApplicationFiled: April 28, 2014Publication date: September 4, 2014Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Michael GRAEBER, Janusz CZERNIELEWSKI
-
Publication number: 20140234420Abstract: The present invention describes methods and compositions for treating diverse dermatological conditions, including acne and psoriasis, using zein containing nanocarrier devices for topical delivery of methotrexate, retinoic acid and benzoyl peroxide to select targets in the skin.Type: ApplicationFiled: August 14, 2013Publication date: August 21, 2014Inventors: Omathanu P. Perumal, Ranjith Kumar Averineni
-
Publication number: 20140234225Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: ApplicationFiled: February 17, 2014Publication date: August 21, 2014Applicant: Alkermes Pharma Ireland LimitedInventors: Christian F. Wertz, Niels P. Ryde
-
Publication number: 20140234455Abstract: An aqueous antimicrobial composition including coniferous resin acids a dispersing agent and an aqueous medium, a method for its preparation and its use as an antimicrobial agent in medical and non-medical field are provided.Type: ApplicationFiled: October 24, 2012Publication date: August 21, 2014Inventor: Pentti Sipponen
-
Patent number: 8808751Abstract: A method for producing a composition comprising nanoparticles of a biologically active compound, comprising the step of: dry milling a solid biologically active compound and a millable grinding compound in a mill comprising a plurality of milling bodies, for a time period sufficient to produce a solid dispersion comprising nanoparticles of the biologically active compound dispersed in an at least partially milled grinding compound is described as are various compositions produced using such methods.Type: GrantFiled: June 29, 2007Date of Patent: August 19, 2014Assignee: Iceutica Pty Ltd.Inventors: Raffaele Cammarano, Felix Meiser, Almar Postma, Frank Caruso
-
Publication number: 20140228334Abstract: Process for producing composite materials by reactive spray-drying, where a liquid phase A, which comprises inorganic cations, and a liquid phase B, which comprises anions which, with the inorganic cations, form a salt that is insoluble in the mixture of the liquid phases are sprayed together using at least one multi-substance nozzle, and where at least one hydrophobic active ingredient is present in dissolved form in at least one liquid spraying phase, and where the salt formed from the cations of phase A and the anions of phase B has a solubility of less than 0.02 mol/l in the neutral aqueous medium.Type: ApplicationFiled: February 7, 2014Publication date: August 14, 2014Applicant: BASF SEInventors: Andreas Kempter, Max Siebert, Heidrun Debus
-
Publication number: 20140221922Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: POLY-MED, INC.Inventors: Shalaby W. Shalaby, David Ingram, Georgios Hilas, Sheila Nagatomi
-
Publication number: 20140213651Abstract: A novel use of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid or a pharmaceutically acceptable salt or functional derivative thereof in treating a cancer, and in particular non-small cell lung cancer, is provided.Type: ApplicationFiled: January 9, 2014Publication date: July 31, 2014Applicant: Biodelight Biotech Inc.Inventor: Thy-Hou LIN
-
Publication number: 20140194520Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.Type: ApplicationFiled: January 17, 2014Publication date: July 10, 2014Applicant: United Therapeutics CorporationInventors: Roger Andrew Jeffs, David Zaccardelli
-
Patent number: 8772273Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.Type: GrantFiled: October 4, 2011Date of Patent: July 8, 2014Assignee: QuRetino Therapeutics, Inc.Inventor: Ferenc Makra
-
Publication number: 20140187504Abstract: The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.Type: ApplicationFiled: June 22, 2012Publication date: July 3, 2014Applicant: GLYCOREREGIMMUNE, INC.Inventor: Vipin Kumar Chaturvedi
-
Patent number: 8759350Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.Type: GrantFiled: December 25, 2003Date of Patent: June 24, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose